BPC 157 Peptide Completely Eliminated Dangerous Heart Rhythm Problems and High Potassium Caused by Succinylcholine in Rats
BPC 157 completely eliminated the hyperkalemia and cardiac arrhythmias caused by succinylcholine while reversing muscle paralysis, damage, and pain in rats.
Quick Facts
What This Study Found
BPC 157 at both 10 µg/kg and 10 ng/kg doses completely eliminated succinylcholine-induced hyperkalemia and cardiac arrhythmias in rats. It also markedly attenuated or eliminated behavioral agitation, muscle twitches, motionless resting, and post-succinylcholine hyperalgesia (pain sensitivity).
BPC 157 immediately eliminated leg contractures and counteracted both edema and the decrease in muscle fibers in the diaphragm and tibial muscles. These protective effects were seen whether BPC 157 was given intraperitoneally 30 minutes before succinylcholine, immediately after, or orally in drinking water for 24 hours prior to succinylcholine administration.
Key Numbers
How They Did This
Rats received succinylcholine (1.0 mg/kg) injected into the right anterior tibial muscle. BPC 157 was administered via three routes: intraperitoneal injection 30 minutes before succinylcholine, intraperitoneal injection immediately after, or orally in drinking water for 24 hours before. Assessments were conducted at 3 min, 30 min, 1 day, 3 days, 5 days, and 7 days post-succinylcholine, evaluating muscle function, serum enzymes, potassium levels, cardiac rhythm, and behavioral outcomes.
Why This Research Matters
Succinylcholine-induced hyperkalemia is a potentially fatal complication during anesthesia. Having a peptide that can prevent or reverse these effects — especially one effective orally — could be clinically significant. This also adds to the growing body of BPC 157 research showing protective effects across multiple organ systems.
The Bigger Picture
BPC 157 is one of the most-studied gastric pentadecapeptides, with over 100 animal studies showing protective effects on muscles, tendons, the gut, brain, and cardiovascular system. This study extends its potential to anesthesiology, where dangerous drug reactions remain a significant clinical concern. However, BPC 157 still lacks human clinical trial data.
What This Study Doesn't Tell Us
This was conducted entirely in rats, and the results have not been replicated in humans. The exact molecular mechanism by which BPC 157 counteracts succinylcholine's effects was not elucidated. The study comes from a research group that publishes extensively on BPC 157, and independent replication by other laboratories would strengthen the evidence. No human pharmacokinetic data exists for BPC 157.
Questions This Raises
- ?What is the molecular mechanism by which BPC 157 prevents succinylcholine-induced hyperkalemia?
- ?Could BPC 157 be used prophylactically before surgery to prevent succinylcholine complications in high-risk patients?
- ?When will BPC 157 be tested in human clinical trials for any indication?
Trust & Context
- Key Stat:
- Complete elimination BPC 157 fully prevented hyperkalemia and cardiac arrhythmias from succinylcholine at both microgram and nanogram doses
- Evidence Grade:
- This is a preclinical animal study in rats. While the results are striking (complete elimination of dangerous side effects), no human data exists for BPC 157, and the study comes from a single research group that is the primary publisher of BPC 157 research.
- Study Age:
- Published in 2016 in the European Journal of Pharmacology. Despite being several years old, BPC 157 still has not entered human clinical trials for any indication, making all evidence preclinical.
- Original Title:
- BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias.
- Published In:
- European journal of pharmacology, 781, 83-91 (2016)
- Authors:
- Stambolija, Vasilije(5), Stambolija, Tamara Perleta, Holjevac, Jadranka Katancic, Murselovic, Tamara, Radonic, Jelena, Duzel, Viktor, Duplancic, Bozidar, Uzun, Sandra, Zivanovic-Posilovic, Gordana, Kolenc, Danijela, Drmic, Domagoj, Romic, Zeljko, Seiwerth, Sven, Sikiric, Predrag
- Database ID:
- RPEP-03120
Evidence Hierarchy
Frequently Asked Questions
What is BPC 157?
BPC 157 (Body Protection Compound-157) is a synthetic pentadecapeptide (15 amino acids) derived from a protein found in human gastric juice. It has shown protective effects across many organ systems in over 100 animal studies, but has not yet been tested in human clinical trials.
Why is succinylcholine dangerous?
Succinylcholine is a muscle relaxant used during surgery and intubation. It can cause hyperkalemia (dangerously high potassium levels), which can lead to fatal cardiac arrhythmias. This risk is especially high in patients with burns, muscle injuries, or certain neurological conditions.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03120APA
Stambolija, Vasilije; Stambolija, Tamara Perleta; Holjevac, Jadranka Katancic; Murselovic, Tamara; Radonic, Jelena; Duzel, Viktor; Duplancic, Bozidar; Uzun, Sandra; Zivanovic-Posilovic, Gordana; Kolenc, Danijela; Drmic, Domagoj; Romic, Zeljko; Seiwerth, Sven; Sikiric, Predrag. (2016). BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias.. European journal of pharmacology, 781, 83-91. https://doi.org/10.1016/j.ejphar.2016.04.004
MLA
Stambolija, Vasilije, et al. "BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias.." European journal of pharmacology, 2016. https://doi.org/10.1016/j.ejphar.2016.04.004
RethinkPeptides
RethinkPeptides Research Database. "BPC 157: The counteraction of succinylcholine, hyperkalemia,..." RPEP-03120. Retrieved from https://rethinkpeptides.com/research/stambolija-2016-bpc-157-the-counteraction
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.